Dr. Maura Dickler presently serves as the Vice President and Global Head, Product Development Oncology, Breast and Gynecologic Cancers at Genentech/Roche. She also serves as voluntary Clinical Assistant Physician at Bellevue/NYU, precepting/teaching oncology fellows in clinic.
Maura joined Genentech in July 2021 after working for more than 20 years as a breast cancer medical oncologist at Memorial Sloan Kettering Cancer Center (MSKCC) in New York. She also served as Vice President of Late Phase Oncology Development at Eli Lilly from 2018 – 2021. She attended The College at the University of Chicago and earned her MD degree at the University of Chicago Pritzker School of Medicine. She completed her residency training at the University of Chicago Hospitals, followed by a fellowship in hematology/medical oncology at MSKCC. In 1998 she joined the faculty and was promoted to an Associate Member of the Breast Medicine Service and an Associate Professor of Medicine at the Weill Medical College of Cornell University. She also served as Section Head of the Endocrine Therapy Clinical Research Program and Interim Head of the Breast Medicine Service.
While at MSKCC, her clinical research focused on developing new therapeutic strategies for the treatment of estrogen receptor (ER)-positive breast cancer. This included the development of biologically rational combinations of drugs targeting important pathways such as the ER, VEGFR, HER2. and PI3K pathways. In addition, she developed agents inhibiting CDK 4 and 6 of the cell cycle. She joined Genentech in 2021 to lead late-phase development for breast and gynecologic cancers, and she oversees the research and development of several therapeutic agents including Perjeta, Kadcyla, Phesgo, inavolisib, giredestrant, camonsertib, atezolizumab and ipatasertib.
